{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:55:01Z","timestamp":1793836501201,"version":"4.6.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed\/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) &amp;lt;40 mL\/min. CrCl &amp;lt;30 mL\/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade \u22653: 1.2% vs 1%) and immune effector cell\u2013associated neurotoxicity syndrome (16% vs 13%; grade \u22653: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade \u22653 anemia and grade \u22653 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016059","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T14:16:52Z","timestamp":1744121812000},"page":"3408-3417","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Teclistamab for patients with heavily pretreated relapsed\/refractory multiple myeloma and renal impairment"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA"},{"name":"2Department of Hematology-Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"3Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh","family":"Goel","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-1771","authenticated-orcid":false,"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2461","authenticated-orcid":false,"given":"Kelley","family":"Julian","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Razzo","sequence":"additional","affiliation":[{"name":"7Department of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"8Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2643-7840","authenticated-orcid":false,"given":"Mariola A.","family":"Vazquez-Martinez","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"9Department of Pharmacy, University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Sannareddy","sequence":"additional","affiliation":[{"name":"3Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Castaneda","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"2Department of Hematology-Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud R.","family":"Gaballa","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-085X","authenticated-orcid":false,"given":"Masooma S.","family":"Rana","sequence":"additional","affiliation":[{"name":"10Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5462-4991","authenticated-orcid":false,"given":"Alex","family":"Lieberman-Cribbin","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"DeJarnette","sequence":"additional","affiliation":[{"name":"12Department of Hematology-Oncology, University of Kansas Medical Center, Kasnas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-7174","authenticated-orcid":false,"given":"Anna","family":"Chen","sequence":"additional","affiliation":[{"name":"7Department of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"13Department of Medicine, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"10Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[{"name":"10Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Ouchveridze","sequence":"additional","affiliation":[{"name":"12Department of Hematology-Oncology, University of Kansas Medical Center, Kasnas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"3Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"12Department of Hematology-Oncology, University of Kansas Medical Center, Kasnas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"2Department of Hematology-Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"11Division of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[{"name":"7Department of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"3Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":false,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"8Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"10Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"8Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Susanibar-Adaniya","sequence":"additional","affiliation":[{"name":"7Department of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"6","key":"2025072209263801100_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2025072209263801100_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"2025072209263801100_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"2025072209263801100_bib4","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"2025072209263801100_bib5","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"2025072209263801100_bib6","first-page":"308.e1","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transpl Cel Ther"},{"issue":"7","key":"2025072209263801100_bib7","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025072209263801100_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma","volume":"1","author":"Yadav","year":"2016","journal-title":"Kidney Dis"},{"issue":"2","key":"2025072209263801100_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"Eleutherakis-Papaiakovou","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2025072209263801100_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17474086.2016.1210003","article-title":"Managing renal complications in multiple myeloma","volume":"9","author":"Fotiou","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"2025072209263801100_bib11","doi-asserted-by":"crossref","first-page":"20406207221088458","DOI":"10.1177\/20406207221088458","article-title":"An overview of treatment options for patients with relapsed\/refractory multiple myeloma and renal impairment","volume":"13","author":"Dimopoulos","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2025072209263801100_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","article-title":"The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies","volume":"9","author":"Hari","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"2025072209263801100_bib13","first-page":"1571","article-title":"Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China","volume":"13","author":"Jian","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2025072209263801100_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2025072209263801100_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2025072209263801100_bib16","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"2025072209263801100_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2025072209263801100_bib18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"8","key":"2025072209263801100_bib19","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2025072209263801100_bib20","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.27063","article-title":"Teclistamab in patients with multiple myeloma and impaired renal function","volume":"98","author":"Joiner","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"2025072209263801100_bib21","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1111\/bjh.19772","article-title":"Teclistamab for relapsed refractory multiple myeloma patients on dialysis","volume":"205","author":"Lebreton","year":"2024","journal-title":"Br J Haematol"},{"issue":"6","key":"2025072209263801100_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1177\/10781552241242022","article-title":"Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis","volume":"30","author":"Khouderchah","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"17","key":"2025072209263801100_bib23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ajhp\/zxac139","article-title":"Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations","volume":"79","author":"Kobayashi","year":"2022","journal-title":"Am J Health Syst Pharm"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3408\/2402052\/blooda_adv-2025-016059-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3408\/2402052\/blooda_adv-2025-016059-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T13:26:43Z","timestamp":1753190803000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/14\/3408\/536605\/Teclistamab-for-patients-with-heavily-pretreated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":23,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016059","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,22]]},"published":{"date-parts":[[2025,7,10]]}}}